ANDA 217194, held by Alkem Laboratories. Lisdexamfetamine Dimesylate.
As of Nov 21, 2026, ANDA 217194 (Lisdexamfetamine Dimesylate), held by Alkem Laboratories, was first approved by FDA on Aug 25, 2023, with 1 approved supplement and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 25, 2023 | Original application | Approved | None posted |
| Lisdexamfetamine Dimesylate10MG · capsule;oral | Lisdexamfetamine Dimesylate | Rx |
| Lisdexamfetamine Dimesylate20MG · capsule;oral | Lisdexamfetamine Dimesylate | Rx |
| Lisdexamfetamine Dimesylate30MG · capsule;oral | Lisdexamfetamine Dimesylate | Rx |
| Lisdexamfetamine Dimesylate40MG · capsule;oral | Lisdexamfetamine Dimesylate | Rx |
| Lisdexamfetamine Dimesylate50MG · capsule;oral | Lisdexamfetamine Dimesylate | Rx |
| Lisdexamfetamine Dimesylate60MG · capsule;oral | Lisdexamfetamine Dimesylate | Rx |
| Lisdexamfetamine Dimesylate70MG · capsule;oral | Lisdexamfetamine Dimesylate | Rx |
| Sep 25, 2024 | Supplement 2Labeling · Standard review | Approved | None posted |
| Aug 25, 2023 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters